Crovalimab for atypical haemolytic uraemic syndrome

Crovalimab is being developed for treating people with atypical haemolytic uraemic syndrome (aHUS). aHUS is an ultra-rare disease caused by a genetic or acquired fault in the part of the
body’s immune response called the complement system, which is responsible for attacking and eliminating bugs. This fault means the complement system attacks normal cells that line blood
vessels and can lead to the formation of clots. These clots can affect any organ in the body, but the kidneys are most commonly affected organ. Symptoms include feeling persistently run down
and, if untreated, aHUS can lead to end-stage kidney failure and death. There are currently few treatment options available for people with aHUS.